Reappearance of influenza B/Victoria/2/87-lineage viruses: Epidemic activity, genetic diversity and vaccination efficacy in the Finnish Defence Forces

Epidemiology and Infection

Volumn 133, Issue 2, 2005, Pages 263-271

  Ikonen, N ^a   Pyhälä, Reijo ^a   Axelin, T ^b   Kleemola, M ^a   Korpela, H ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b CENTRAL MILITARY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE;

ADULT; ARMY; ARTICLE; AUTUMN; CONTROLLED STUDY; EPIDEMIC; FINLAND; GENETIC REASSORTMENT; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HYPOTHESIS; INCIDENCE; INFLUENZA VACCINATION; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN;

ADOLESCENT; ADULT; ANTIBODY FORMATION; DISEASE OUTBREAKS; FINLAND; HUMANS; INCIDENCE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MILITARY PERSONNEL; PHYLOGENY;

EID: 15944411009     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268804003462     Document Type: Article

References (38)

1. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175: 59-68.
2. Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 1992; 73: 2737-2742.
3. Hay AJ, Lin YP, Gregory V, Bennett M. Annual Report, August 2001 to July 2002. WHO Collaborating Centre for Reference and Research on Influenza. London: National Institute for Medical Research, 2002.
4. Hungnes O. The role of genetic analysis in influenza virus surveillance and strain characterisation. Vaccine 2002; 20: B45-B49.
5. Shaw MW, Xu X, Li Y, et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 2002; 303: 1-8.
6. Ansaldi F, D'Agaro P, de Florentiis D, et al. Molecular characterization of influenza B viruses circulating in Northern Italy during the 2001-2002 epidemic season. J Med Virol 2003; 70: 463-469.
7. Pyhälä R. Influenza surveillance during the 1987-1988 epidemic season in Finland: antigenic drift and vaccination problems [in Finnish]. Suom Laakaril 1988; 43: 3261-3268.
8. Kinnunen L, Ikonen N, Pöyry T, Pyhälä R. Evolution of influenza B/Victoria/2/87-like viruses: occurrence of a genetically conserved virus under conditions of low epidemic activity. J Gen Virol 1992; 73: 733-736.
9. Ikonen N, Kinnunen L, Forsten T, Pyhälä R. Recent influenza B viruses in Europe: a phylogenetic analysis. Clin Diagn Virol 1996; 6: 63-71.
10. Anonymous. Recommended composition of influenza virus vaccines for use in the 2002-2003 season. Wkly Epidemiol Rec 2002; 77 62-67.
11. Chi XS, Bolar TV, Zhao P, Rappaport R, Cheng S-M. Cocirculation and evolution of two lineages of influenza B viruses in Europe and Israel in the 2001-2002 season. J Clin Microbiol 2003; 41 5770-5773.
12. Pyhälä R, Visakorpi R, Ikonen N, Kleemola M. Influence of antigenic drift on the intensity of influenza outbreaks: upper respiratory tract infections of military conscripts in Finland. J Med Virol 2004; 72: 275-280.
13. Pyhälä R, Haanpää M, Kleemola M, Tervahauta R, Visakorpi R, Kinnunen L. Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine 2001; 19: 3253-3260.
14. Pyhälä R, Kleemola M, Kumpulainen V, et al. Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages. Vaccine 1992; 10: 631-636.
15. Halonen P, Meurman O, Lövgren T, Hemmilä I, Soini E. Detection of viral antigens by time-resolved fluoroimmunoassay. Curr Top Microbiol Immunol 1983; 104: 133-146.
16. Casey HL. Standardized diagnostic complement fixation method and adaptation to micro test. Public Health Monogr 1965; 74: 31-34.
17. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: U.S. Department of Health and Human Services, Centres for Disease Control and Prevention, 1982.
18. Nakagawa N, Nukuzuma S, Haratome S, Go S, Nakagawa T, Hayashi K. Emergence of an influenza B virus with antigenic change. J Clin Microbiol 2002; 40: 3068-3070.
19. Infectious Diseases in Finland 2002. Helsinki, National Public Health Institute, 2002; KTL B10.
20. Pyhälä R, Ikonen N, Korpela H, et al. Surveillance of influenza during the 2002/2003 epidemic season in Finland: an expected virus at an unexpected time [in Finnish with English summary]. Suom Laakaril 2003; 58: 3897-3902.
21. Infectious Diseases in Finland 2003. National Public Health Institute, 2004; KTL B9.
22. Daly JM, Wood JM, Robertson JS. Cocirculation and divergence of human influenza viruses. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford: Blackwell Science Ltd, 1998: 168-177.
23. McCullers J, Wang GC, He S, Webster RG. Reassortment and insertion-detetion are strategies for the evolution of influenza B viruses in nature. J Virol 1999; 73: 7343-7348.
24. Hay AJ, Lin YP, Gregory V, Bennett M. Annual Report, August 2002 to August 2003. WHO Collaborating Centre for Reference and Research on Influenza. London: National Institute for Medical Research, 2003.
25. Barr IG, Komadina N, Hurt A, et al. Reassortants in recent human influenza A and B isolates from South East Asia and Oceania. Virus Res 2003; 98: 35-44.
26. Matsuzaki Y, Sugawara K, Takashita E, et al. Genetic diversity of influenza B virus: the frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community. J Med Virol 2004; 74: 132-140.
27. Skehel JJ, Stevens DJ, Daniels RS, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 1984; 81: 1779-1783.
28. Inkster MD, Hinshaw VS, Schulze IT. The hemagglutinins of duck and human H1 influenza viruses differ in sequence conservation and in glycosylation. J Virol 1993; 67: 7436-7443.
29. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143: 166-174.
30. Rota PA, Shaw MW, Kendal AP. Comparison of the immune response to variant influenza type B hemagglutinins expressed in vaccinia virus. Virology 1987; 161: 269-275.
31. Robertson JS, Bootman JS, Nicolson C, Major D, Robertson EW, Wood JM. The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. Virology 1990; 179: 35-40.
32. Gambaryan AS, Robertson JS, Matrosovich MN. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 1999; 258: 232-239.
33. Saito T, Nakaya Y, Suzuki T, et al. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J Med Virol 2004; 74: 336-343.
34. Nakagawa N, Kubota R, Maeda A, Nakagawa T, Okuno Y. Heterogeneity of influenza B virus strains in one epidemic season differentiated by monoclonal antibodies and nucleotide sequences. J Clin Microbiol 2000; 38: 3467-3469.
35. Muyanga J, Matsuzaki Y, Sugawara K, et al. Antigenic and genetic analyses of influenza B viruses isolated in Lusaka, Zambia in 1999. Arch Virol 2001; 146: 1667-1679.
36. Davenport FM. Control of influenza. Med J Aust 1973; 1 (Suppl): 33-38.
37. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J Infect Dis 1983; 148: 775-784.
38. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21: 1769-1775.